Key Highlights

  • Shares of SELLAS Life Sciences (NASDAQ:SLS) dropped 13.98% to USD 15.44 after the company floated a proposed USD 150.0 million public raise on November 17, 2026, following Phase 3 REGAL survival results.
  • PepGen (NASDAQ:PEPG) shares rose 8.82% to USD 4.16, which is about 16.8% below the USD 5.00 offering price (calculated), with no news dated today.
  • ARS Pharmaceuticals (NASDAQ:SPRY) slid 7.62% to USD 3.41 without any located announcement. The latest hard figures showed USD 37.7 million of third-quarter sales and a smaller deficit.
  • Evolent Health (NYSE:EVH) shares fell 5.47% to USD 3.71 with no announcement located, while its medical expense ratio rose to 93.0% from 85.0% a year earlier.

SELLAS Life Sciences (NASDAQ:SLS): Phase 3 Success Meets a Share Sale

The stock was marked down 13.98% at USD 15.44 on Thursday, November 19, 2026. Working back from that, the prior close sits near USD 17.95 by calculation. Of the four names here, it is the only one tied to a company-announced catalyst. On November 17, 2026, the company reported that galinpepimut-S, examined in acute myeloid leukaemia in the Phase 3 REGAL study, met its primary endpoint of overall survival. Median survival reached 24.0 months for treated patients against 14.7 months for those on best available treatment, with a hazard ratio of 0.59 and a p-value of 0.035. The next step was an underwritten offering, proposed at USD 150.0 million. Underwriters hold a 30-day option on up to USD 22.5 million of extra stock, and J.P. Morgan and TD Cowen run the books. Since the company is the only seller, fresh shares enlarge the share base and dilute current holders. No per-share price was stated and final pricing has not been confirmed, so the discount to market is unknown. Cash was USD 134.7 million on September 30, 2026, against 203,527,833 shares outstanding. Caution is warranted given the open-label design across 126 patients, a p-value that is only just under the 0.05 threshold, and the possibility of a regulator seeking extra data. Filing preparations for a Biologics License Application target the first half of 2027. Thin trading in names like this can make the quoted price swing.

PepGen (NASDAQ:PEPG): A Rebound That Stays Below the USD 5.00 Pricing

Intraday data shows PepGen (NASDAQ:PEPG) at USD 4.16, up 8.82%, yet the quote remains about 16.8% under what buyers paid in the recent offering, a simple calculation from two published figures. No company announcement dated November 17 to 19 turned up, so the gain has no identified event behind it. Pricing for the raise came on November 11, 2026, with 25 million shares placed at USD 5.00 apiece, which would bring in USD 125 million before costs. Underwriters hold an option for up to 3.75 million more shares over 30 days. Neither the closing nor any exercise of the option has been verified in this review. Phase 2 results for PGN-EDODM1, a treatment studied in myotonic dystrophy type 1, preceded the raise. The 10 mg/kg group recorded mean splicing correction of 46.5%, with five of six participants above 20% and four above 50%. Adding gross raise proceeds before fees to that balance gives about USD 229.8 million (calculated), against USD 104.8 million of cash at September 30, 2026. On a net basis, the third quarter ended in a USD 19.4 million loss. A partial clinical hold placed by the FDA in March 2026 is the chief hazard, since it delays a regulatory meeting slated for the second half of 2027. Dilution and the swings typical of a low-priced stock add to that risk.

ARS Pharmaceuticals (NASDAQ:SPRY): Decline With No Named Driver

The stock changed hands at USD 3.41 on November 19, 2026, a 7.62% decline that places the prior close near USD 3.69 by calculation. Research turned up no company announcement, filing or analyst action dated November 17 to 19, so no cause can be given. Hard figures last came from the November 5, 2026 third-quarter report. Sales hit USD 37.7 million, compared with USD 32.5 million. The United States net product line for neffy, the needle-free epinephrine nasal spray, reached USD 33.4 million from USD 31.3 million, which is growth of about 6.7% (calculated). The loss narrowed to USD 35.6 million, or USD 0.36 a share, as selling costs fell to USD 43.5 million from USD 74.8 million. Management said end-user Demand ran ahead of recorded revenue, citing swings in channel inventory. Liquidity stood at USD 138.4 million in cash and short-term holdings, versus roughly USD 245.0 million at the close of 2025. That roughly USD 107 million drop is a calculated figure. Breakeven on Cash Flow is the goal for the end of 2027, which means a delay would leave funding as the real exposure. A term Loan of roughly USD 121.8 million was mentioned in published coverage, and no filing confirmed it.

Evolent Health (NYSE:EVH): Revenue Jump Paired With Thinner Margins

On November 19, 2026, Evolent Health (NYSE:EVH) changed hands at USD 3.71, down 5.47% in intraday figures. No announcement accounting for the move surfaced, and the latest verified item dates from the November 5, 2026 third-quarter release. That release showed growth alongside thinner profitability. Revenue came in at USD 725.4 million against USD 479.5 million. Adjusted EBITDA, however, dropped to USD 34.3 million, down from USD 39.0 million. For risk-based contracts, the medical expense ratio tracks how much revenue goes toward care costs. That ratio rose to 93.0% from 85.0%, and the adjusted EBITDA Margin shrank to 4.7% from 8.1%. Management raised its 2026 adjusted EBITDA outlook to a range of USD 130.0 million to USD 135.0 million, while the revenue outlook of USD 2.6 billion through USD 2.7 billion was left unchanged. Leverage is the central worry: cash of USD 148.3 million sits against USD 969.5 million of net long-term debt, which comes to roughly USD 821.2 million after deducting that cash (calculated). The first use would target Debt reduction, with up to USD 50 million earmarked before year-end, though contract wins need time before they show in margins.

Where Things Stand

These four moves share a sector but no single cause. SELLAS Life Sciences (NASDAQ:SLS) is the only one with an announced driver, a USD 150.0 million raise after its Phase 3 data, which accompanies the 13.98% decline. PepGen (NASDAQ:PEPG) gained 8.82% yet sits beneath the USD 5.00 offering price, and no same-day news was located. ARS Pharmaceuticals (NASDAQ:SPRY) dropped 7.62% without any announcement found. Evolent Health (NYSE:EVH) fell 5.47% on identical grounds, so neither slide should be pinned on a single event. Financing is the link: share dilution at SELLAS and PepGen, cash consumption at ARS, plus debt at Evolent. Upcoming markers include the SELLAS pricing terms and an FDA session, the PepGen clinical hold and data due in January 2027, an ARS-2 readout due during the first quarter of 2027, and Evolent's debt paydown by year-end. None of this guarantees how these shares will trade.